ReviewCancers2019
Antioxidant Defenses: A Context-Specific Vulnerability of Cancer Cells.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 54 citations in OpenAlex.
- Potential Anticancer Effect ofInternational journal of molecular sciences · 2025Article
- DDR2 Confers Ferroptosis Resistance to Cancer-Associated Fibroblasts and Attenuates PARPi Sensitivity of Ovarian Tumor Cells.Molecular cancer research : MCR · 2025Article
- Exploring Neuroprotection against Radiation-Induced Brain Injury: A Review of Key Compounds.NeuroSci · 2024Review
- Discovery of the Inhibitor Targeting the SLC7A11/xCT Axis through In Silico and In Vitro Experiments.International journal of molecular sciences · 2024Article
- Multitarget Pharmacology of Sulfur-Nitrogen Heterocycles: Anticancer and Antioxidant Perspectives.Antioxidants (Basel, Switzerland) · 2024Review
- Dual Stimuli-Responsive Nanoprecursor of Ascorbic Acid and Quinone Methide Disrupting Redox Homeostasis for Cancer Treatment.ACS omega · 2024Article
- Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathways.Journal of translational medicine · 2024Article
- Therapeutic controversies over use of antioxidant supplements during cancer treatment: a scoping review.Frontiers in nutrition · 2024Article
- Ferroptosis and oral squamous cell carcinoma: connecting the dots to move forward.Frontiers in oral health · 2024Review
- The master antioxidant defense is activated during EBV latent infection.Journal of virology · 2023Article
- Pepper Fruit Extracts Show Anti-Proliferative Activity against Tumor Cells Altering Their NADPH-Generating Dehydrogenase and Catalase Profiles.Antioxidants (Basel, Switzerland) · 2023Article
- Modulation of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment by Natural Products.Archivum immunologiae et therapiae experimentalis · 2023Review
- Antioxidant, Anti-Inflammatory and Anti-Proliferative Properties ofPlants (Basel, Switzerland) · 2023Article
- Carrimycin, a first in-class anti-cancer agent, targets selenoprotein H to induce nucleolar oxidative stress and inhibit ribosome biogenesis.Cancer pathogenesis and therapy · 2023Article
- KSHV hijacks FoxO1 to promote cell proliferation and cellular transformation by antagonizing oxidative stress.Journal of medical virology · 2023Article
- Antioxidant and Anti-Inflammatory Compounds from Edible Plants with Anti-Cancer Activity and Their Potential Use as Drugs.Molecules (Basel, Switzerland) · 2023Review
- Iron affects the sphere-forming ability of ovarian cancer cells in non-adherent culture conditions.Frontiers in cell and developmental biology · 2023Article
- Iron imbalance in cancer: Intersection of deficiency and overload.Cancer medicine · 2022Review
- Antioxidant Activity of New Sulphur- and Selenium-Containing Analogues of Potassium Phenosan against HCurrent issues in molecular biology · 2022Article
- The Protective Anticancer Effect of Natural Lycopene Supercritical COAntioxidants (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Reactive oxygen species (ROS) are well known for their capacity to cause DNA damage, augment mutagenesis, and thereby promote oncogenic transformation. Similarly, agents that reduce ROS levels (antioxidants) are frequently thought to have anti-cancer properties given their propensity to minimize DNA damage and mutagenesis. However, numerous clinical studies focused on antioxidants suggest that this is a facile premise and that antioxidant capacity can be important for cancer cells in a similar fashion to normal cells. As a consequence of this realization, numerous laboratories have been motivated to investigate the biological underpinnings explaining how and when antioxidant activity can potentially be beneficial to cancer cells. Relatedly, it has become clear that the reliance of cancer cells on antioxidant activity in certain contexts represents a potential vulnerability that could be exploited for therapeutic gain. Here, we review some of the recent, exciting findings documenting how cancer cells utilized antioxidant activity and under what circumstances this activity could represent an opportunity for selective elimination of cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.